Thromboregulatory strategies to prolong xenograft survival.
延长异种移植物存活的血栓调节策略。
基本信息
- 批准号:7086952
- 负责人:
- 金额:$ 59.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:CD antigensanticoagulantsantigen antibody reactionbaboonsbiotechnologyblood chemistryblood coagulation disordersgenetic manipulationgenetically modified animalsgraft versus host diseasehistocompatibilityimmunosuppressionkidney transplantationpancreatic islet transplantationplatelet activating factorplatelet activationregulatory geneswinethrombinthrombocytopathythrombomodulintranscription factortransplant rejectiontransplantation immunologyurinalysisxenotransplantation
项目摘要
DESCRIPTION (provided by applicant): Xenotransplantation may be clinically feasible once the molecular barriers between species and mechanisms of graft loss or rejection are better understood. Xenograft survival would have to be also achieved without compromising the recipient to the extent that systemic toxicity would be encountered. In this regard, genetic engineering of swine, with xenograft modification to provide greater compatibility, has been of recent interest. Thrombotic and inflammatory reactions to porcine bone marrow (BM)-derived cells, infused pancreatic islets and the vasculature of organ grafts are linked to the difficulties in establishing mixed discordant chimerism, pancreatic islet-associated procoagulant injury and the development of xenograft microangiopathy. These responses are likely associated with humoral immune reactions to xenogeneic tissues. However, thrombotic processes with progressive xenograft vascular injury and infarction may be further exacerbated by documented intrinsic molecular incompatibilities in regulation of blood clotting between discordant species. An example of this would be the failure of natural porcine anticoagulants, such as thrombomodulin, to interact with human/primate coagulation factors, such as thrombin and Protein C. The development of the GalT-KO pig and consequent removal of the dominant xeno-antigen have been a major advance in xenotransplantation research. However, problems still persist in inducing tolerance by generating mixed xenogeneic chimerism, either by vascularized thymic tissues or the BM-derived cell approach in baboons. GalT-KO islets have not yet been tested but the current GalT-KO renal and cardiac xenograft limited survival times and associated vascular injury patterns still preclude clinical application. The goals of this application are to effectively manage graft thrombotic and vascular sequelae associated with GalT-KO pig-to-baboon renal grafting and those complications seen in islet xenotransplantation. We will evaluate transgenic approaches to over-express CD39, a key thromboregulatory protein and/or thrombomodulin in pigs. Transgenic porcine vascularized renal grafts and pancreatic islets over-expressing these human factors will be transplanted into baboons. Our strategies will include optimal immunosuppressive interventions with protocols to attempt induction of tolerance. These studies will be judged successful if novel, clinically relevant antithrombotic therapies can be then developed and applied.
描述(由申请人提供):一旦物种之间的分子屏障和移植物丢失或排斥的机制得到更好的理解,异种移植可能在临床上是可行的。异种移植物的存活也必须在不损害受体的情况下达到可能遇到全身毒性的程度。在这方面,猪的基因工程,与异种移植修饰,以提供更大的兼容性,已成为最近的兴趣。猪骨髓(BM)来源细胞、输注胰岛和器官移植血管的血栓和炎症反应与建立混合不协调嵌合的困难、胰岛相关的促凝剂损伤和异种移植物微血管病变的发展有关。这些反应可能与对异种组织的体液免疫反应有关。然而,进行性异种移植物血管损伤和梗死的血栓形成过程可能会进一步加剧,因为在不一致物种之间的血液凝固调节中存在固有的分子不相容。这方面的一个例子是,天然猪抗凝血剂(如血栓调节素)无法与人/灵长类动物凝血因子(如凝血酶和c蛋白)相互作用。GalT-KO猪的开发和随后的显性异种抗原的去除是异种移植研究的一个重大进展。然而,在狒狒中,通过产生混合异种嵌合来诱导耐受性的问题仍然存在,无论是通过血管化胸腺组织还是bm衍生细胞方法。GalT-KO胰岛尚未测试,但目前GalT-KO肾脏和心脏异种移植有限的生存时间和相关的血管损伤模式仍然阻碍了临床应用。本应用的目的是有效地处理与GalT-KO猪到狒狒肾移植相关的移植物血栓和血管后遗症以及在胰岛异种移植中看到的并发症。我们将评估转基因方法来过度表达CD39,这是一种关键的凝血调节蛋白和/或凝血调节蛋白。转基因猪血管化肾移植物和过度表达这些人类因子的胰岛将被移植到狒狒体内。我们的策略将包括最佳的免疫抑制干预方案,以尝试诱导耐受性。如果能够开发和应用新的临床相关抗血栓治疗方法,这些研究将被认为是成功的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SIMON C. ROBSON其他文献
SIMON C. ROBSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SIMON C. ROBSON', 18)}}的其他基金
Engineering Inhibitory Antibodies to Ectoenzymes for Cancer Treatment
用于癌症治疗的胞外酶工程抑制性抗体
- 批准号:
8309768 - 财政年份:2012
- 资助金额:
$ 59.58万 - 项目类别:
Engineering Inhibitory Antibodies to Ectoenzymes for Cancer Treatment
用于癌症治疗的胞外酶工程抑制性抗体
- 批准号:
8451262 - 财政年份:2012
- 资助金额:
$ 59.58万 - 项目类别:
Thromboregulatory Barriers to Xenotransplantation
异种移植的血栓调节障碍
- 批准号:
8190128 - 财政年份:2011
- 资助金额:
$ 59.58万 - 项目类别:
Thromboregulatory strategies to prolong xenograft survival.
延长异种移植物存活的血栓调节策略。
- 批准号:
7898491 - 财政年份:2009
- 资助金额:
$ 59.58万 - 项目类别:
Thromboregulatory strategies to prolong xenografts
延长异种移植时间的血栓调节策略
- 批准号:
6987599 - 财政年份:2005
- 资助金额:
$ 59.58万 - 项目类别:
Thromboregulatory strategies to prolong xenograft survival.
延长异种移植物存活的血栓调节策略。
- 批准号:
7658192 - 财政年份:2005
- 资助金额:
$ 59.58万 - 项目类别:
Thromboregulatory strategies to prolong xenograft survival.
延长异种移植物存活的血栓调节策略。
- 批准号:
7256900 - 财政年份:2005
- 资助金额:
$ 59.58万 - 项目类别:
Thromboregulatory Barriers to Xenotransplantation
异种移植的血栓调节障碍
- 批准号:
6964790 - 财政年份:2005
- 资助金额:
$ 59.58万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 59.58万 - 项目类别:
Operating Grants
Anticoagulant use, safety, and effectiveness for venous thromboembolism prevention in inflammatory bowel disease patients
炎症性肠病患者预防静脉血栓栓塞的抗凝剂使用、安全性和有效性
- 批准号:
10887842 - 财政年份:2023
- 资助金额:
$ 59.58万 - 项目类别:
Platelet Metabolic Stress Induces Thrombo-Inflammation to Drive Endothelial Dysfunction in PH
PH 中血小板代谢应激诱导血栓炎症导致内皮功能障碍
- 批准号:
10736724 - 财政年份:2023
- 资助金额:
$ 59.58万 - 项目类别:
Targeting HNF4-induced thrombo-inflammation in Chagas disease
针对恰加斯病中 HNF4 诱导的血栓炎症
- 批准号:
10727268 - 财政年份:2023
- 资助金额:
$ 59.58万 - 项目类别:
MLL1 drives collaborative leukocyte-endothelial cell signaling and thrombosis after coronavirus infection
MLL1在冠状病毒感染后驱动白细胞-内皮细胞信号传导和血栓形成
- 批准号:
10748433 - 财政年份:2023
- 资助金额:
$ 59.58万 - 项目类别:
Michigan Emergency Department Improvement Collaborative AltERnaTives to admission for Pulmonary Embolism (MEDIC ALERT PE) Study
密歇根急诊科改进合作入院肺栓塞 (MEDIC ALERT PE) 研究
- 批准号:
10584217 - 财政年份:2023
- 资助金额:
$ 59.58万 - 项目类别:
Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation
开发合成肝素以保护移植肝免受移植过程中的缺血再灌注损伤
- 批准号:
10759102 - 财政年份:2023
- 资助金额:
$ 59.58万 - 项目类别:
Personalized Risk Stratification in Atrial Fibrillation using Portable, Explainable Artificial Intelligence
使用便携式、可解释的人工智能对心房颤动进行个性化风险分层
- 批准号:
10905154 - 财政年份:2023
- 资助金额:
$ 59.58万 - 项目类别:
Tele-Sox: A Tele-Medicine solution based on wearables and gamification to prevent Venous thromboembolism in Oncology Geriatric Patients
Tele-Sox:基于可穿戴设备和游戏化的远程医疗解决方案,用于预防肿瘤老年患者的静脉血栓栓塞
- 批准号:
10547300 - 财政年份:2023
- 资助金额:
$ 59.58万 - 项目类别: